One in eight. That is the proportion of deaths prevented among children eligible for the RTS,S malaria vaccine in Ghana, Kenya, and Malawi over four years of deployment. Translated into human lives: more than 13,000 African children have escaped death thanks to this vaccine developed over 35 years by GlaxoSmithKline.
This major breakthrough in global health, however, collides with a brutal paradox: while the vaccine’s effectiveness is confirmed in the field, international funding for malaria control is eroding. Gavi’s malaria program, the Vaccine Alliance, is showing a 30% deficit, threatening the expansion of a tool that finally works.
The Essentials
- 1 in 8 deaths prevented among vaccinated children in Ghana, Kenya, and Malawi according to the WHO
- 25 African countries now deploying the RTS,S vaccine with 39 million doses delivered
- International malaria funding shows a 30% deficit according to Gavi
- Artemisinin resistance, the standard treatment, is progressing in East Africa
35 Years of Development for a Confirmed Success
The RTS,S epitomizes the complexity of medical innovation in Africa. Initiated in 1987 by GlaxoSmithKline in partnership with the charity organization PATH, this vaccine required three decades of research to achieve modest but real effectiveness: 39% reduction in malaria episodes in children aged 5 to 17 months.
The pilot program results, published by the WHO in May 2026, validate this approach on a large scale. In Ghana, 1.7 million children received at least one dose. In Kenya, 2.3 million. In Malawi, 1.6 million. Across these three countries, the analysis reveals a 13% reduction in all-cause mortality in eligible children, an impact that exceeded initial projections.
This performance conceals a remarkable logistical success. Integrating a new vaccine into African health systems, often fragile, represents a major technical challenge. The RTS,S requires four injections: three initial doses followed by a booster. This complexity did not prevent 70% coverage for the first dose in pilot zones.
25 African Countries Cross the Deployment Threshold
The vaccine’s geographic expansion is drawing a new health map of Africa. Benin, Burkina Faso, Cameroon, Chad, Democratic Republic of the Congo, Ghana, Liberia, Malawi, Niger, Sierra Leone: ten countries launched national introduction in 2024. Fifteen others, including Nigeria, the demographic giant of 230 million inhabitants, are preparing their deployment for 2026-2027.
This surge is backed by 39 million doses already delivered by Gavi since 2019. Production, ensured by the GlaxoSmithKline plant in Wavre, Belgium, will reach 15 million doses annually by 2027. A second vaccine, R21/Matrix-M developed by Oxford University and produced by the Serum Institute of India, will complement the arsenal with an additional 25 million doses per year.
The demographic impact becomes measurable. In areas where artemisinin, the standard treatment, shows signs of resistance, the vaccine now constitutes the first line of defense. Uganda and Tanzania, where mutations of the P. Falciparum parasite reduce therapeutic effectiveness by 15% to 20%, are betting on vaccine prevention to maintain disease control.
International Funding Loses Momentum
Gavi’s figures reveal the fragility of this expansion. The malaria program shows a 30% deficit over the 2026-2030 period, roughly 2 billion dollars missing. This shortage occurs at the moment when African demand is exploding: 40 countries have expressed interest in introducing the vaccine.
This underfunding reflects broader donor fatigue among traditional contributors. The United States, the principal historical contributor via PEPFAR (President’s Emergency Plan for AIDS Relief) and the Gates Foundation, maintains its commitments but is no longer increasing allocations. The European Union, the second largest funder, is concentrating its resources on Ukraine and migration. The United Kingdom, the fourth largest global health donor until 2020, has reduced its development aid from 0.7% to 0.5% of GDP.
This tight financial equation coincides with the emergence of therapeutic resistance in Africa. The first artemisinin-resistant P. Falciparum strains, detected in Southeast Asia in the 2010s, have crossed the Indian Ocean. Uganda, Rwanda, and Tanzania are reporting rising therapeutic failure rates. Without strengthening vaccine prevention, antibiotic resistance migrates from poor countries to rich countries according to international mobility circuits.
China and India Redefine Africa’s Vaccine Ecosystem
Faced with Western exhaustion, new players are restructuring vaccine supply. The Serum Institute of India, the world’s largest vaccine producer by volume, is investing 200 million dollars in R21/Matrix-M production. This industrial capacity allows the vaccine to be offered at 3 dollars per dose, compared to 9.30 dollars for GlaxoSmithKline’s RTS,S.
China is taking a different approach. Beijing is betting on local production of generic antimalarial drugs and technical assistance rather than vaccines. The China-Africa Cooperation on Health, a program launched in 2024, is training 1,500 African technicians in rapid diagnostic techniques. This strategy prioritizes African therapeutic autonomy over Western vaccine dependence.
This geopolitical reshuffling concerns traditional players. Seth Berkley, Gavi’s executive director until 2023, observes that “Africa is diversifying its health partners as it diversifies its business partners.” A dynamic that is accelerating: three African countries—Ghana, Kenya, Rwanda—are negotiating directly with the Serum Institute, bypassing UN mechanisms.
Real Efficacy Redefines National Strategies
Field data are modifying national cost-benefit calculations. In Malawi, the introduction of RTS,S coincided with a 17% drop in pediatric consultations for fever. In Ghana, regional hospitals report a 23% decrease in hospitalizations for severe malaria in 12-23 month-olds. These hospital gains free up resources for other diseases.
Economic impact becomes quantifiable. A study by the Pasteur Institute in Dakar calculates that preventing one child death through vaccination generates an average of 12 additional years of life. Valued according to WHO criteria—3 times GDP per capita per year of life saved—these gains represent 36,000 dollars per life preserved in average African economies.
This profitability is pushing some governments toward self-financing. Botswana, Africa’s leading economy by GDP per capita, has fully financed its vaccination program since 2025. South Africa is evaluating a mixed system: free vaccination in poor provinces, co-payment in wealthy urban areas.
Toward a New Architecture for Health Financing
The future of the malaria vaccine is sketching the contours of post-Western global health. When supply determines demand, funding mechanisms evolve: pandemic bonds issued by the World Bank, taxes on financial transactions, levies on pharmaceutical profits.
Three scenarios are emerging for 2030. The first: reinforced traditional financing maintains Western hegemony but limits geographic expansion. The second: Chinese-Indian emergence makes access cheaper but fragments standards. The third: a hybrid system combines multilateral financing and decentralized production.
Artemisinin resistance could settle this debate. If therapeutic failures reach 30% in East Africa by 2028, vaccination will become the only viable option. In this scenario, the RTS,S’s modest effectiveness—one child saved in eight—would be enough to justify continental deployment, regardless of cost.